ストックスクリーナーアプリを入手
2.46
3.36%
0.08
前日終値:
$2.38
開ける：
$2.41
24時間の取引高:
316.42K
Relative Volume:
0.45
時価総額：
$81.72M
収益：
$63.26M
当期純損益:
$-32.92M
株価収益率:
-20.59
EPS:
-0.1195
ネットキャッシュフロー:
$-71.34M
1週間 パフォーマンス:
+9.82%
1か月 パフォーマンス:
-5.38%
6か月 パフォーマンス:
-0.81%
1年 パフォーマンス:
+38.20%
1日の値動き範囲:
$2.38
$2.47
1週間の範囲:
$2.20
$2.47
52週間の値動き範囲:
$1.60
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
名前
Fortress Biotech Inc
セクター
電話
781-652-4500
住所
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.46 | 79.06M | 63.26M | -32.92M | -71.34M | -0.1195 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-15 | 再開されました | ROTH MKM | Buy |
| 2022-08-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-02 | 開始されました | The Benchmark Company | Buy |
| 2019-12-18 | 開始されました | B. Riley FBR | Buy |
| 2018-02-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
| 2017-03-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-10-03 | 開始されました | ROTH Capital | Buy |
すべてを表示
Fortress Biotech Inc (FBIO) 最新ニュース
Fortress Biotech CEO to speak at royalty company virtual conference - Stock Titan
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - marketscreener.com
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
FBIOP Stock Price, Quote & Chart | FORTRESS BIOTECH INCFBIO 9 3/8 PERP (NASDAQ:FBIOP) - ChartMill
MSN Money - MSN
FBIO Stock Price, Quote & Chart | FORTRESS BIOTECH INC (NASDAQ:FBIO) - ChartMill
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Executive pay, ownership and auditor up for vote at Fortress Biotech (NASDAQ: FBIO) - Stock Titan
Why Is Fortress Biotech Stock Falling Today? - MSN
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Fortress (FBIOP) Market Conditions | Fortress Biotech pref posts 108.9% steep EPS missInvestor Call - Cổng thông tin điện tử tỉnh Lào Cai
Fortress (FBIOP) Investment Case | Q4 2025: Earnings Fall ShortCrowd Trend Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Rosacea drug Emrosi expands access to over 150 million U.S. lives - Stock Titan
(FBIOP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Fortress Biotech Inc stock (US32015L1035): Is the pipeline strength now the real test for investors? - AD HOC NEWS
FBIO | Fortress Biotech, Inc. Insider Trading - Quiver Quantitative
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Is Fortress Biotech (FBIO) Stock a Long-Term Buy? (Trend Weakens) 2026-04-16Value Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Aug Spikes: Is Fortress Biotech Inc part of any ETFPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Is Fortress Biotech (FBIO) Stock Cheap at Current Price | Price at $2.44, Up 3.62%Debt Free Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Growth Value: How does Fortress Biotech Inc score in quality rankingsDay Trade & High Conviction Investment Ideas - baoquankhu1.vn
Sectors Review: Should value investors consider Fortress Biotech Inc2026 Performance Recap & Community Trade Idea Sharing Platform - baoquankhu1.vn
Liquidity Mapping Around (FBIOP) Price Events - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB) - The Globe and Mail
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Maintains Target Price $4.5 - Moomoo
Institution Moves: Does Fortress Biotech Inc stock benefit from AI growth2026 Volume Leaders & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Is Fortress Biotech (FBIO) Stock better than industry peers | Price at $2.35, Down 6.37%Fast Rising Picks - Xã Vĩnh Công
Is Fortress (FBIOP) Stock Discounted Now | Price at $13.62, Up 0.26%Fundamental Analysis - Cổng thông tin điện tử tỉnh Tây Ninh
FBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fortress Biotech Inc (FBIO) Stock Price, Trades & News - GuruFocus
FBIO PE Ratio & Valuation, Is FBIO Overvalued - Intellectia AI
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
FBIO SEC FilingsFortress Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS - MarketBeat
Fortress Biotech: Q4 Earnings Snapshot - Barchart.com
Fortress Biotech 2025 10-K: Revenue $63.3M, GAAP net loss $(32.9)M - TradingView
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) boosts cash with PRV sale, royalties - Stock Titan
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
Fortress Biotech Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView — Track All Markets
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Fortress Biotech Subsidiary Sells Rare Disease Priority Voucher for $205M - National Today
Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital - TipRanks
Fortress Biotech (NASDAQ: FBIO) targets $100M+ from Cyprium PRV sale - Stock Titan
Cyprium Therapeutics sells rare disease priority review voucher for $205 million - StreetInsider
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes - GlobeNewswire
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - Bitget
Why (FBIOP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Fortress Biotech Inc (FBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):